#713: No More Incremental Change: The Radical Future of Healthcare
Thursday, June 18, 2026 11:00 AM to 12:30 PM · 1 hr. 30 min. (America/New_York)
114
00: Plenary03: Data-Tech-AI08: RegPolicy-Strategy-GlobalCollaboration
Information
This closing session brings together pioneering voices at the intersection of AI, advanced computing, and biopharma to explore how a new intelligence layer is rewiring the entire life sciences value chain—from discovery to delivery. The discussion will examine how foundational AI, cloud-scale infrastructure, and digital platforms are reshaping R&D, clinical development, manufacturing, and patient engagement. The conversation will highlight not only breakthrough opportunities—smarter target discovery, more adaptive trials, real-world evidence at scale, and hyper-personalized care—but also the governance, ethics, workforce, and partnership models needed to harness these technologies responsibly in a highly regulated environment.
Session Level
Intermediate
Learning Objectives
Describe key ways AI and other advanced digital technologies are reshaping the life sciences value chain; Discuss concrete examples of how leading pharma and tech companies are using digital platforms, cloud infrastructure, and AI to accelerate R&D and improve patient outcomes; Evaluate key risks and governance challenges associated with deploying powerful AI and data technologies in regulated life sciences settings, including bias, transparency, and accountability.
Speakers

Eli Weinberg
PartnerBain & Co.
Carlos Garner
Senior Vice-President Global Regulatory Affairs and Head, Lilly Regenerative MedEli Lilly and Company
Shweta Maniar
Global Director, Strategic Industries - Life SciencesGoogle
Susan Furth
Executive Vice President and Chief Scientific OfficerChildren's Hospital of Philadelphia
Dhruv Jayanth
Business Lead, Life SciencesOpenAI